CD274 and nasopharyngeal carcinoma: Based on the preclinical evidence and promising results of anti-PD-1/PDL-1 immune checkpoint inhibitors in RM-NPC, the addition of immunotherapy in the current combined treatment modalities for LA-NPC is a hot clinical research topic, and many prospective phase II or III trials are ongoing (25).